{"id":"NCT00790738","sponsor":"Northwell Health","briefTitle":"Liothyronine (T3) for Bipolar Depression","officialTitle":"Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2008-11-13","resultsPosted":"2015-07-02","lastUpdate":"2015-07-02"},"enrollment":11,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression","Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Liothyronine (T3)","otherNames":["cytomel (liothyronine)"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.","primaryOutcome":{"measure":"Hamilton Rating Scale for Depression Scores","timeFrame":"8 weeks","effectByArm":[{"arm":"Liothyronine (T3)","deltaMin":3.5,"sd":3.54},{"arm":"Placebo","deltaMin":7.25,"sd":5.44}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":["Insomnia","Increased Appetite","excitment","Hypersomnia","Headache"]}}